The role of fatty aldehyde dehydrogenase in epidermal structure and function

Dermato-Endocrinology

Volumn 3, Issue 2, 2011, Pages 91-99

  Rizzo, William B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Epidermis; Fatty alcohol; Ichthyosis; Lamellar body; Membranes; Sj gren Larsson syndrome; Stratum corneum

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE; ALDEHYDE DEHYDROGENASE; CERAMIDE; FATTY ALCOHOL; ISOPRENALINE; LEUKOTRIENE B4;

ALCOHOL METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; EPIDERMIS; EXOCYTOSIS; FATTY ACID OMEGA OXIDATION; FIBROBLAST; HUMAN; KERATINOCYTE; LAMELLAR BODY; LIPID STORAGE; LIPOLYSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SJOEGREN LARSSON SYNDROME; SKIN FUNCTION; SKIN STRUCTURE;

EID: 79956087845     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.3.2.14619     Document Type: Review

References (104)

1. Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991; 24:1-26.
2. Madison KC. Barrier function of the skin: "la raison d̂tre" of the epidermis. J Invest Dermatol 2003; 121:231-41.
3. Feingold KR. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res 2007; 48:2531-46. (Pubitemid 350272838)
4. Feingold KR. The outer frontier: the importance of lipid metabolism in the skin. J Lipid Res 2009; 50:417-22.
5. Mao-Qiang M, Elias PM, Feingold KR. Fatty acids are required for epidermal permeability barrier function. J Clin Invest 1993; 92:791-8. (Pubitemid 23262400)
6. Feingold KR, Man MQ, Menon GK, Cho SS, Brown BE, Elias PM. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest 1990; 86:1738-45. (Pubitemid 20372628)
7. Holleran WM, Man MQ, Gao WN, Menon GK, Elias PM, Feingold KR. Sphingolipids are required for mammalian epidermal barrier function. Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J Clin Invest 1991; 88:1338-45.
8. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 2008; 49:697-714.
9. Rizzo WB. Sjogren-Larsson syndrome: fatty aldehyde dehydrogenase deficiency. In: The metabolic & molecular bases of inherited disease. New York, NY: McGraw-Hill, 2001:2239-58.
10. Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders. Acta Psychiatr Neurol Scand 1957; 32:1-113.
11. De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, et al. Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 1996; 12:52-7.
12. Rizzo WB, Carney G. Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum Mutat 2005; 26:1-10. (Pubitemid 40983989)
13. + oxidoreductase in cultured fibroblasts. J Clin Invest 1991; 88:1643-8.
14. Kelson TL, Secor McVoy JR, Rizzo WB. Human liver fatty aldehyde dehydrogenase: microsomal localization, purification and biochemical characterization. Biochim Biophys Acta 1997; 1335:99-110. (Pubitemid 27174510)
15. Keller MA, Watschinger K, Golderer G, Maglione M, Sarg B, Lindner HH, et al. Monitoring of fatty aldehyde dehydrogenase by formation of pyrenedecanoic acid from pyrenedecanal. J Lipid Res 2010; 51:1554-9.
16. Rogers GR, Markova NG, De Laurenzi V, Rizzo WB, Compton JG. Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH). Genomics 1997; 39:127-35. (Pubitemid 27069210)
17. Masaki R, Yamamoto A, Tashiro Y. Microsomal aldehyde dehydrogenase is localized to the endoplasmic reticulum via its carboxyl-terminal 35 amino acids. J Cell Biol 1994; 126:1407-20. (Pubitemid 24284606)
18. Ashibe B, Hirai T, Higashi K, Sekimizu K, Motojima K. Dual subcellular localization in the endoplasmic reticulum and peroxisomes and a vital role in protecting against oxidative stress of fatty aldehyde dehydrogenase are achieved by alternative splicing. J Biol Chem 2007; 282:20763-73. (Pubitemid 47100018)
19. Rizzo WB, S'Aulis D, Jennings MA, Crumrine DA, Williams ML, Elias PM. Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion. Arch Dermatol Res 2010; 302:443-51.
20. Judge MR, Lake BD, Smith VV, Besley GT, Harper JI. Depletion of alcohol (hexanol) dehydrogenase activity in the epidermis and jejunal mucosa in Sjögren-Larsson syndrome. J Invest Dermatol 1990; 95:632-4.
21. Jagell S, Lidén S. Ichthyosis in the Sjögren-Larsson syndrome. Clin Genet 1982; 21:243-52.
22. Auada MP, Adam RL, Leite NJ, Puzzi MB, Cintra ML, Rizzo WB, Metze K. Texture analysis of the epidermis based on fast Fourier transformation in Sjögren-Larsson syndrome. Anal Quant Cytol Histol 2006; 28:219-27. (Pubitemid 44162598)
23. Shibaki A, Akiyama M, Shimizu H. Novel ALDH3A2 heterozygous mutations are associated with defective lamellar granule formation in a Japanese family of Sjögren-Larsson syndrome. J Invest Dermatol 2004; 123:1197-9. (Pubitemid 39586847)
24. Matsuoka LY, Kousseff BG, Hashimoto K. Studies of the skin in Sjögren-Larsson syndrome by electron microscopy. Am J Dermatopathol 1982; 4:295-301. (Pubitemid 13232978)
25. Ito M, Oguro K, Sato Y. Ultrastructural study of the skin in Sjögren-Larsson syndrome. Arch Dermatol Res 1991; 283:141-8.
26. Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, et al. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol 2001; 117:837-47. (Pubitemid 33001199)
27. Ichihara K, Kusunose E, Noda Y, Kusunose M. Some properties of the fatty alcohol oxidation system and reconstitution of microsomal oxidation activity in intestinal mucosa. Biochim Biophys Acta 1986; 878:412-8. (Pubitemid 16033316)
28. Ichihara K, Noda Y, Tanaka C, Kusunose M. Purification of aldehyde dehydrogenase reconstitutively active in fatty alcohol oxidation from rabbit intestinal microsomes. Biochim Biophys Acta 1986; 878:419-25. (Pubitemid 16033317)
29. + oxidoreductase from rat liver. J Biol Chem 1979; 254:2892-6.
30. Rizzo WB, Craft DA, Dammann AL, Phillips MW. Fatty alcohol metabolism in cultured human fibroblasts. Evidence for a fatty alcohol cycle. J Biol Chem 1987; 262:17412-9. (Pubitemid 18032217)
31. Rizzo WB, Craft DA. Sjögren-Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J Lipid Res 2000; 41:1077-81. (Pubitemid 30483011)
32. Rizzo WB, Dammann AL, Craft DA, Black SH, Tilton AH, Africk D, et al. Sjögren-Larsson syndrome: inherited defect in the fatty alcohol cycle. J Pediatr 1989; 115:228-34. (Pubitemid 19190342)
33. Rizzo WB, Dammann AL, Craft DA. Sjögren-Larsson syndrome. Impaired fatty alcohol oxidation in cultured fibroblasts due to deficient fatty alcohol:nicotinamide adenine dinucleotide oxidoreductase activity. J Clin Invest 1988; 81:738-44. (Pubitemid 18079721)
34. Nicolaides N. The monoene and other Wax alcohols of human skin surface lipid and their relation to the fatty acids of this lipid. Lipids 1967; 2:266-75.
35. Oku H, Shudo J, Mimura K, Haratake A, Nagata J, Chinen I. 1-O-alkyl-2,3-diacylglycerols in the skin surface lipids of the hairless mouse. Lipids 1995; 30:169-72.
36. Rizzo WB, Craft DA, Somer T, Carney G, Trafrova J, Simon M. Abnormal fatty alcohol metabolism in cultured keratinocytes from patients with Sjögren-Larsson syndrome. J Lipid Res 2008; 49:410-9. (Pubitemid 351213626)
37. Oku H, Shudo J, Nagata J, Chinen I. Accumulation of 1-o-alkyl-2,3- diacylglycerols in cultured rat keratinocytes. Biochim Biophys Acta 1996; 1300:35-41. (Pubitemid 26103897)
38. van den Brink DM, Wanders RJ. Phytanic acid: production from phytol, its breakdown and role in human disease. Cell Mol Life Sci 2006; 63:1752-65. (Pubitemid 44223084)
39. van den Brink DM, van Miert JN, Dacremont G, Rontani JF, Jansen GA, Wanders RJ. Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic acid. Mol Genet Metab 2004; 82:33-7. (Pubitemid 38521126)
40. Jansen GA, Wanders RJ. Alpha-oxidation. Biochim Biophys Acta 2006; 1763:1403-12.
41. Verhoeven NM, Jakobs C, Carney G, Somers MP, Wanders RJ, Rizzo WB. Involvement of microsomal fatty aldehyde dehydrogenase in the alpha-oxidation of phytanic acid. FEBS Lett 1998; 429:225-8. (Pubitemid 28300365)
42. Jansen GA, van den Brink DM, Ofman R, Draghici O, Dacremont G, Wanders RJ. Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid alpha-oxidation pathway is localized in peroxisomes. Biochem Biophys Res Commun 2001; 283:674-9. (Pubitemid 32917943)
43. Roullet J-B, Steiner R, Rizzo W. Impaired isoprenoid metabolism in Sjögren-Larsson syndrome. J Inherit Metab Dis 2006; 29:49.
44. Crick DC, Andres DA, Waechter CJ. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 1997; 237:483-7. (Pubitemid 27434709)
45. Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett 2010; 287:123-35.
46. Nagan N, Zoeller RA. Plasmalogens: biosynthesis and functions. Prog Lipid Res 2001; 40:199-229. (Pubitemid 32220187)
47. Horrocks LA. Plasmalogens and O-alkyl glycerophospholipids. In: Hawthorne JN, Editors. Phospholipids. New York: Elsevier Biomedical Press 1982; 51-93.
48. Taguchi H, Armarego WL. Glyceryl-ether monooxygenase [EC 1.14.16.5]. A microsomal enzyme of ether lipid metabolism. Med Res Rev 1998; 18:43-89.
49. Rizzo WB, Heinz E, Simon M, Craft DA. Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjögren-Larsson syndrome. Biochim Biophys Acta 2000; 1535:1-9.
50. Uchida Y, Holleran WM. Omega-O-acylceramide, a lipid essential for mammalian survival. J Dermatol Sci 2008; 51:77-87.
51. Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277:25847-50. (Pubitemid 34967060)
52. Uchida Y, Houben E, Park K, Douangpanya S, Lee YM, Wu BX, et al. Hydrolytic pathway protects against ceramide-induced apoptosis in keratinocytes exposed to UVB. J Invest Dermatol 2010; 130:2472-80.
53. Serra M, Saba JD. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 2010; 50:349-62.
54. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11:81-128. (Pubitemid 121003917)
55. Alary J, Guéraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. Mol Aspects Med 2003; 24:177-87. (Pubitemid 36945018)
56. Pappa A, Estey T, Manzer R, Brown D, Vasiliou V. Human aldehyde dehydrogenase 3A1 (ALDH3A1): biochemical characterization and immunohistochemical localization in the cornea. Biochem J 2003; 376:615-23. (Pubitemid 38063115)
57. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008; 4:697-720. (Pubitemid 352003194)
58. Demozay D, Rocchi S, Mas JC, Grillo S, Pirola L, Chavey C, Van Obberghen E. Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin. J Biol Chem 2004; 279:6261-70. (Pubitemid 38258224)
59. Demozay D, Mas JC, Rocchi S, Van Obberghen E. FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes. Diabetes 2008; 57:1216-26.
60. Stadelmann-Ingrand S, Favreliere S, Fauconneau B, Mauco G, Tallineau C. Plasmalogen degradation by oxidative stress: production and disappearance of specific fatty aldehydes and fatty alpha-hydroxyaldehydes. Free Radic Biol Med 2001; 31:1263-71. (Pubitemid 33052502)
61. Albert CJ, Crowley JR, Hsu FF, Thukkani AK, Ford DA. Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: identification of 2-chlorohexadecanal. J Biol Chem 2001; 276:23733-41.
62. Wildsmith KR, Albert CJ, Anbukumar DS, Ford DA. Metabolism of myeloperoxidase-derived 2-chlorohexadecanal. J Biol Chem 2006; 281:16849-60.
63. Anbukumar DS, Shornick LP, Albert CJ, Steward MM, Zoeller RA, Neumann WL, Ford DA. Chlorinated lipid species in activated human neutrophils: lipid metabolites of 2-chlorohexadecanal. J Lipid Res 2010; 51:1085-92.
64. Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007; 405:379-95. (Pubitemid 47172035)
65. Willemsen MA, Rotteveel JJ, de Jong JG, Wanders RJ, IJlst L, Hoffmann GF, Mayatepek E. Defective metabolism of leukotriene B4 in the Sjögren-Larsson syndrome. J Neurol Sci 2001; 183:61-7. (Pubitemid 32141074)
66. Reynaud D, Rounova O, Demin PM, Pivnitsky KK, Pace-Asciak CR. Hepoxilin A3 is oxidized by human neutrophils into its omega-hydroxy metabolite by an activity independent of LTB4 omega-hydroxylase. Biochim Biophys Acta 1997; 1348:287-98. (Pubitemid 27464816)
67. Kikuta Y, Kusunose E, Kusunose M. Prostaglandin and leukotriene omega-hydroxylases. Prostaglandins Other Lipid Mediat 2002; 68:345-62.
68. Sanders RJ, Ofman R, Dacremont G, Wanders RJ, Kemp S. Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids. FASEB J 2008; 22:2064-71. (Pubitemid 351811482)
69. Franks NP, Lieb WR. Partitioning of long-chain alcohols into lipid bilayers: implications for mechanisms of general anesthesia. Proc Natl Acad Sci USA 1986; 83:5116-20. (Pubitemid 16051327)
70. Miller KW, Firestone LL, Alifimoff JK, Streicher P. Nonanesthetic alcohols dissolve in synaptic membranes without perturbing their lipids. Proc Natl Acad Sci USA 1989; 86:1084-7. (Pubitemid 19056295)
71. Ferreira GC, Patton JS. Inhibition of lipolysis by hydrocarbons and fatty alcohols. J Lipid Res 1990; 31:889-97. (Pubitemid 20175015)
72. Bikle DD, Ng D, Tu CL, Oda Y, Xie Z. Calcium- and vitamin D-regulated keratinocyte differentiation. Mol Cell Endocrinol 2001; 177:161-71. (Pubitemid 32506816)
73. Denning MF, Kazanietz MG, Blumberg PM, Yuspa SH. Cholesterol sulfate activates multiple protein kinase C isoenzymes and induces granular cell differentiation in cultured murine keratinocytes. Cell Growth Differ 1995; 6:1619-26.
74. Ikuta T, Chida K, Tajima O, Matsuura Y, Iwamori M, Ueda Y, et al. Cholesterol sulfate, a novel activator for the eta isoform of protein kinase C. Cell Growth Differ 1994; 5:943-7. (Pubitemid 24275108)
75. Bollag WB. Differentiation of human keratinocytes requires the vitamin d receptor and its coactivators. J Invest Dermatol 2007; 127:748-50. (Pubitemid 46434668)
76. Denning MF. Epidermal keratinocytes: regulation of multiple cell phenotypes by multiple protein kinase C isoforms. Int J Biochem Cell Biol 2004; 36:1141-6. (Pubitemid 38515654)
77. Warne TR, Buchanan FG, Robinson M. Growthdependent accumulation of monoalkylglycerol in Madin-Darby canine kidney cells. Evidence for a role in the regulation of protein kinase C. J Biol Chem 1995; 270:11147-54.
78. McNeely TB, Rosen G, Londner MV, Turco SJ. Inhibitory effects on protein kinase C activity by lipophosphoglycan fragments and glycosylphosphatidylinositol antigens of the protozoan parasite Leishmania. Biochem J 1989; 259:601-4. (Pubitemid 19111701)
79. Ford DA, Miyake R, Glaser PE, Gross RW. Activation of protein kinase C by naturally occurring ether-linked diglycerides. J Biol Chem 1989; 264:13818-24. (Pubitemid 19198475)
80. Slater SJ, Kelly MB, Larkin JD, Ho C, Mazurek A, Taddeo FJ, et al. Interaction of alcohols and anesthetics with protein kinase Calpha. J Biol Chem 1997; 272:6167-73. (Pubitemid 27118084)
81. Van den Branden C, Vamecq J, Wybo I, Roels F. Phytol and peroxisome proliferation. Pediatr Res 1986; 20:411-5. (Pubitemid 16107007)
82. James PF, Zoeller RA. Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff 's base modification of phospholipids: implications for Sjögren- Larsson syndrome. J Biol Chem 1997; 272:23532-9. (Pubitemid 27410921)
83. Stadelmann-Ingrand S, Pontcharraud R, Fauconneau B. Evidence for the reactivity of fatty aldehydes released from oxidized plasmalogens with phosphatidylethanolamine to form Schiff base adducts in rat brain homogenates. Chem Phys Lipids 2004; 131:93-105. (Pubitemid 38802865)
84. Hanley K, Kömüves LG, Ng DC, Schoonjans K, He SS, Lau P, et al. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 2000; 275:11484-91. (Pubitemid 30212804)
85. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008; 49:499-509.
86. Meigs TE, Roseman DS, Simoni RD. Regulation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 1996; 271:7916-22. (Pubitemid 26108608)
87. Hinson DD, Chambliss KL, Toth MJ, Tanaka RD, Gibson KM. Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J Lipid Res 1997; 38:2216-23. (Pubitemid 27495380)
88. Menon GK, Feingold KR, Mao-Qiang M, Schaude M, Elias PM. Structural basis for the barrier abnormality following inhibition of HMG CoA reductase in murine epidermis. J Invest Dermatol 1992; 98:209-19.
89. Feingold KR, Man MQ, Proksch E, Menon GK, Brown BE, Elias PM. The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia. J Invest Dermatol 1991; 96:201-9.
90. Lefèvre C, Bouadjar B, Ferrand V, Tadini G, Mé garbané A, Lathrop M, et al. Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 2006; 15:767-76. (Pubitemid 43264701)
91. Nigam S, Zafiriou MP, Deva R, Ciccoli R, Roux-Van der Merwe R. Structure, biochemistry and biology of hepoxilins: an update. FEBS J 2007; 274:3503-12. (Pubitemid 47052415)
92. Pace-Asciak CR, Reynaud D, Demin P, Nigam S. The hepoxilins. A review. Adv Exp Med Biol 1999; 447:123-32.
93. Yu Z, Schneider C, Boeglin WE, Brash AR. Mutations associated with a congenital form of ichthyosis (NCIE) inactivate the epidermal lipoxygenases 12RLOX and eLOX3. Biochim Biophys Acta 2005; 1686:238-47. (Pubitemid 40039150)
94. Jobard F, Lefèvre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, et al. Lipoxygenase-3 (ALOXE3) and 12®-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 2002; 11:107-13. (Pubitemid 34100773)
95. Yu Z, Schneider C, Boeglin WE, Brash AR. Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARalpha. Lipids 2007; 42:491-7. (Pubitemid 46988480)
96. Collins XH, Harmon SD, Kaduce TL, Berst KB, Fang X, Moore SA, et al. Omega-oxidation of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4. J Biol Chem 2005; 280:33157-64. (Pubitemid 41398202)
97. Willemsen MA, de Jong JG, van Domburg PH, Rotteveel JJ, Wanders RJ, Mayatepek E. Defective inactivation of leukotriene B4 in patients with Sjögren-Larsson syndrome. J Pediatr 2000; 136:258-60. (Pubitemid 30471002)
98. Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J Invest Dermatol 2001; 117:1621-6.
99. Willemsen MA, Lutt MA, Steijlen PM, Cruysberg JR, van der Graaf M, Nijhuis-van der Sanden MW, et al. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 2001; 160:711-7.
100. Mao-Qiang M, Feingold KR, Jain M, Elias PM. Extracellular processing of phospholipids is required for permeability barrier homeostasis. J Lipid Res 1995; 36:1925-35.
101. Hernell O, Holmgren G, Jagell SF, Johnson SB, Holman RT. Suspected faulty essential fatty acid metabolism in Sjögren-Larsson syndrome. Pediatr Res 1982; 16:45-9. (Pubitemid 12200710)
102. Wertz PW, Swartzendruber DC, Abraham W, Madison KC, Downing DT. Essential fatty acids and epidermal integrity. Arch Dermatol 1987; 123:1381-4. (Pubitemid 17152307)
103. Paige DG, Morse-Fisher N, Harper JI. Quantification of stratum corneum ceramides and lipid envelope ceramides in the hereditary ichthyoses. Br J Dermatol 1994; 131:23-7. (Pubitemid 24234283)
104. Avigan J, Campbell BD, Yost DA, Hernell O, Holmgren G, Jagell SF. Sjögren-Larsson syndrome: delta 5-and delta 6-fatty acid desaturases in skin fibroblasts. Neurology 1985; 35:401-3. (Pubitemid 15100683)